Opportunistic prostate‐specific antigen testing in Norwegian men: a public health challenge
BJU International · 2024-01 · 133 (1) · 104-111
DOI: 10.1111/bju.16211 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, online erschienen am 02.11.2023. Verfasst von Peter C Albertsen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery (Urology), UConn Health, Farmington, CT, USA. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Objective
To describe age‐specific prostate‐specific antigen (PSA) distributions and resulting prostate cancer diagnoses that arise from population‐wide opportunistic PSA testing. Patients and Methods Over 8 million PSA tests were performed on >1.4 million Norwegian men from 2000 to 2020. During this period 43 486 men were diagnosed with localised prostate cancer. Most of the PSA testing reflected opportunistic testing. Age‐specific PSA value distributions were constructed for men aged 45–75 years with and without prostate cancer.
Results
The distributions of PSA values in men with and without prostate cancer widened with age and overlapped extensively from 3 to 7 ng/mL. Localised prostate cancer diagnoses increased 10‐fold from the age of 45 to 75 years. PSA testing identified intermediate‐ or high‐grade cancers in 21% (95% confidence interval [CI] 19–23%) of men aged 50–54 years and 42% (95% CI 41–43%) of men aged 70–74 years. Grade group (GG)1, GG2, GG3 and ≥GG4 constituted 49%, 31%, 10% and 10% of cancers identified at age 50–54 years and 26%, 26%, 18%, and 30% of cancers identified at age 70–74 years.
Conclusion
Opportunistic PSA testing increases with ageing and often generates values that cannot discriminate benign prostate enlargement from prostate cancer. A clinical cascade using additional imaging or serum tests is necessary to avoid negative biopsies and the overdiagnosis of indolent disease. The declining specificity of PSA testing with ageing poses a significant public health challenge especially among older men aged ≥70 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery (Urology), UConn Health, Farmington, CT, USA.
- Department of Clinical Chemistry, Fürst Laboratories, Oslo, Norway.
- Department of Urology, Akershus University Hospital, Lørenskog, Norway.
- Medical Faculty, University of Oslo, Oslo, Norway.
- Department of Oncology, Oslo University Hospital, Oslo, Norway.
- Department of Surgery (Urology Service) and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Albertsen, P. C., Bjerner, L. J., Pasovic, L., Müller, S., Fosså, S., Carlsson, S. V., & Oldenburg, J. (2024). Opportunistic prostate‐specific antigen testing in Norwegian men: a public health challenge. BJU International, 133(1), 104-111. https://doi.org/10.1111/bju.16211
Vancouver
Albertsen PC, Bjerner LJ, Pasovic L, Müller S, Fosså S, Carlsson SV, et al. Opportunistic prostate‐specific antigen testing in Norwegian men: a public health challenge. BJU International. 2024;133(1):104-111. doi:10.1111/bju.16211
BibTeX
@article{Albertsen2024,
author = {Albertsen, Peter C and Bjerner, Lars Johan and Pasovic, Lara and Müller, Stig and Fosså, Sophie and Carlsson, Sigrid V and Oldenburg, Jan},
title = {Opportunistic prostate‐specific antigen testing in Norwegian men: a public health challenge},
journal = {BJU International},
year = {2024},
volume = {133},
number = {1},
pages = {104--111},
doi = {10.1111/bju.16211}
}
EUVIMED